Prospective Study of the Immune Effects of Normalizing the Hemoglobin Concentration in Hemodialysis Patients Who Receive Recombinant Human Erythropoietin

Roman, Renato M B; Lobo, Peter I.; Taylor, Ronald P.; Goodkin, David A.; LaBrecque, J.F.; Powers, Kathy; Bolton, W. Kline

doi:10.1097/01.asn.0000125618.27422.c7

Cited by 28 publications

(16 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anaemia is associated with an increased risk of the vascular complications of diabetes including nephropathy [7,25,26], retinopathy [27,28], neuropathy [3], impaired wound healing [29] and macrovascular disease. A reduced Hb, even within the normal range, identifies patients with type 2 diabetes who are at increased risk of progressive renal disease, hospitalisation and premature death [7].…”

Section: Does Anaemia Contribute To Diabetic Complications?mentioning

confidence: 99%

Anaemia in diabetes: is there a rationale to TREAT?

et al. 2006

View full text Add to dashboard Cite

Section: Does Anaemia Contribute To Diabetic Complications?mentioning

confidence: 99%

Anaemia in diabetes: is there a rationale to TREAT?

et al. 2006

View full text Add to dashboard Cite

“…However, some indication of improved immunity after introduction of rHuEpo might be noted as changed TH1/TH2 balance towards TH1 cytokines as found in our earlier work [2]. Improvement in cellular responses associated with administration of rHuEpo was reported by several centres [2,5,14,20,21]. We have to admit that, at least in our hands, the effect was not direct since rHuEpo receptors have not been found on mature lymphocytes, and also the majority of our in vitro studies excluded such direct interactions [7].…”

Section: Discussionmentioning

confidence: 85%

“…They are focused mainly on improvement in general condition of the patients [6]. Following rHuEpo rejuvenates CD8 þ T cell compartment 3223 this concept, recovery of cellular immunity seems to be secondary to the normalization of haemoglobin levels [20]. However, recently described protective actions of both endogenous Epo or rHuEpo on the cells of epithelium, cardiac muscle, pancreatic islets and brain implicate that a much wider range of possible interactions might exist [22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Treatment with recombinant human erythropoietin is associated with rejuvenation of CD8+ T cell compartment in chronic renal failure patients

Trzonkowski

Dębska-Ślizień

Myśliwski

et al. 2007

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Background. A growing body of evidence suggests an impact of rHuEpo on the immune system. Methods. We assessed the impact of recombinant human erythropoietin (rHuEpo) on the immunity of 11 chronic renal failure patients who did not require haemodialysis. Naı¨ve (Tn), central (Tcm) and effectory memory (Tcm, Tem, TemRA) subsets of CD8þ T cells, memory-CMVspecific CD8þ T cells, titres of anti-CMV antibodies and activity of NK cells were evaluated during the first year of rHuEpo administration. Results. While the number of CD8 T cells did not change, significant change was found in their proportions. Percentage of Tn cells increased at the expense of Tcm cells. Appearing Tn cells were CD28þ increasing the total pool of CD28þ T cells. Together with decreasing number, Tcm cells changed to mainly CD28À Tcm cells. A 'move' towards the naı¨ve compartment was also confirmed as the level of memory-CMV-specific CD8þ T cells decreased. Humoral immunity analysed as titres of anti-CMV antibodies as well as innate immunity measured as cytotoxicity of NK cells did not change during the follow-up. Conclusions. We found that the administration of rHuEpo caused rejuvenation of cellular CD8þ T-dependent immunity in our patients.

show abstract

“…Therefore, HD patients usually received packed RBC transfusion if their haemoglobin was low. Today, EPO is available commercially and is commonly given to patients on dialysis [13,14,15]. Patients can have the EPO which can increase RBC production from the bone marrow and decrease the chance of anaemia…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Antibody to Hepatitis E Virus among Haemodialysis Patients in Taiwan: Possible Infection by Blood Transfusion

Lee¹,

Shih²,

Laio³

et al. 2005

Nephron Clin Pract

View full text Add to dashboard Cite

Background/Aims: A higher prevalence of anti-hepatitis E virus (HEV) in non-endemic viral hepatitis such as in Germany has been reported in our previous study. The aim of this study was to assess the seroepidemiology of HEV among haemodialysis (HD) patients in Shin-Kong Hospital, Taiwan, and to evaluate whether there was an increased risk of infection and exposure to HEV even in an area of endemic viral hepatitis. Methods: Serum samples obtained from 400 Taiwanese patients on chronic HD (group 1), 400 sex- and age-matched healthy subjects (group 2) and hospital patients (group 3) were tested for the IgG anti-HEV. Results: The prevalence of anti-HEV among the HD patients and the healthy controls were 31 and 8.9%, respectively. The difference (22%) was statistically significant (p < 0.01). In comparison, the anti-HEV in hospital patients was 16%. Conclusion: The study indicated a significantly higher risk of HEV infection among patients on chronic HD in endemic regions of viral hepatitis such as Taiwan. Mostly because of anaemia, HD patients usually received packed transfusion (red blood cells) if their haemoglobin was low. It is possible that HEV infection may be transmitted through blood transfusions in an endemic area. In such areas, appropriate strategies should be adopted to prevent the risk of HEV among HD patients.

show abstract

Prospective Study of the Immune Effects of Normalizing the Hemoglobin Concentration in Hemodialysis Patients Who Receive Recombinant Human Erythropoietin

Abstract: Abstract. Partial correction of anemia by erythropoietin improves hemodialysis (HD)-associated immunosuppression.

Cited by 28 publications

References 28 publications

Anaemia in diabetes: is there a rationale to TREAT?

Anaemia in diabetes: is there a rationale to TREAT?

Treatment with recombinant human erythropoietin is associated with rejuvenation of CD8+ T cell compartment in chronic renal failure patients

Prevalence of Antibody to Hepatitis E Virus among Haemodialysis Patients in Taiwan: Possible Infection by Blood Transfusion

Contact Info

Product

Resources

About